




Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

13. 10. 2004



Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03024202.8

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03024202.8
Demande no:

Anmeldetag:
Date of filing: 21.10.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Vitamins AG
Grenzacherstrasse 124
4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Stabilisation of pufa ester concentrates

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C11B/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Bemerkungen:
Remarks:
Remarques:

The application was transferred from the above mentioned original applicant to:
DSM IP Assets B.V - Heerlen - NL.
The registration of the changes has taken effect on 14.01.04.

Fax Cover Sheet

To:	Europäisches Patentamt, München	Tel. +49 89 23 99-0 Fax +49 89 23 99 44 65
Copies:		
From:	Dr. W. Mezger	Roche Vitamins Ltd Patent Department CH-4070 Basel Tel. +41-61-688 62 67 Fax +41-61-688 32 41
Date:	October 21, 2003	
No. of pages:	17 (incl. cover sheet)	

Roche Vitamins AG, CH-4070 Basle, Switzerland

Case 22223

Stabilisation of PUFA Ester Concentrates

Today there is reasonable evidence that increasing dietary levels of unsaturated fatty acids can reduce the incidence of death from coronary heart diseases via effects on blood pressure, atherosclerosis, and thrombogenesis.

5 The unsaturated fatty acids comprise monounsaturated fatty acids (MUFAs), e.g., oleic and palmitoleic acid, and polyunsaturated fatty acids (PUFA). Examples of n-6 PUFAs are linoleic acid ($C_{18} : 2$) and arachidonic acid ($C_{20} : 4$), examples of n-3 PUFAs are α -linolenic acid ($C_{18} : 3$), eicosapentaenoic acid (EPA, $C_{20} : 5$), and docosahexaenoic acid (DHA, $C_{22} : 6$). Especially EPA and DHA have attracted interest of the food industry in
10 recent years. The most available sources of these two fatty acids are fish and the marine oils extracted from them.

With increasing number of double bonds the PUFAs are subject to increasing oxidative degradation and development of undesirable "off-flavors", mainly fishy smell and taste. The increasing interest in the PUFAs, especially long-chain PUFAs (LCPUFAs),
15 such as EPA and DHA, has prompted research in methods of refining and stabilization of fish oils and concentrates of PUFAs.

It has been known for a long time that freshly refined marine oils are initially free from off-flavors and a taste and smell of fish but that reversion through oxidation occurs rapidly. Many attempts have been made to stabilize the oils by the addition of different
20 anti-oxidants of mixtures thereof. However, all these attempts have failed so far or still left open the possibility of further improvements (see, e.g. Hamilton, R.J. et al., Journal of American Oil and Chemists' Society (JAOCS), 75, 813-822 [1998]).

Refined marine oil which has been treated with silica and been stabilised by addition of a mixture of lecithin, ascorbyl palmitate and alpha tocopherol and subsequent soft

- 2 -

vacuum deodorisation at a temperature between about 140°C and 210°C in accordance with the procedure described in European patent publication No. 612 346 shows excellent Rancimat stability and good application performance mainly for health food supplements. In dairy applications such as yoghurts and milk drinks, however, this oil develops a strong fish smell and taste.

Refined marine oils which have been treated according to the procedure described in European patent publication No. 340 635, i.e. by vacuum steam distillation and treatment with an adsorbent such as silica gel or silicic acid, and which has been stabilised with 0.1% deodorised rosemary extract (HERBALOX "O", Kalsec, Inc. of Kalamazoo, Michigan) or sage extract has a herby taste and smell which can be detected in food applications. This herby taste and smell suppresses the taste and smell of fish. In dairy applications, however, the use of as little as 0.03% of HERBALOX "O" and, respectively, sage extract in the marine oil results in a very strong herby taste and smell which prevents the use of this oil in these applications.

According to European patent application publication No. 999 259 fully refined marine oils which have been neutralized, bleached and deodorized in a conventional manner are stabilized over a long period of time without the occurrence of fishy taste and smell by treatment with silica, optionally in the presence of carbon, vacuum steam deodorization at a temperature between about 140°C and about 210°C in the presence of 0.1-0.4% of rosemary or sage extract and, optionally, after deodorization, addition of 0.01-0.03% ascorbyl palmitate and 0.05-0.2% mixed tocopherols.

However, when applying that method in a pilot trial to a concentrate of PUFA ethyl esters the result was disappointing and demonstrated that this procedure is not good enough for stabilisation of PUFA ester concentrates. To 20 kg of a mixture containing 40-50% ethyl EPA and 20-30% ethyl DHA 0.2% of rosemary extract (HERBALOX "O") was added before the deodorization at 140°C followed by addition of 0.1% mixed tocopherols and 0.02% of ascorbyl palmitate after deodorisation. Immediately on completion of the deodorisation and cool down to room temperature the esters had a mild and not fishy taste. The esters were packaged into aluminium containers in a glove box under nitrogen for future stability testing. The first sampling took place two weeks after production and the esters were rejected as having a very strong fish taste and smell.

In accordance with the present invention, it has been found, however, that addition of a combination of rosemary or sage extract, mixed tocopherols and ascorbyl palmitate before the deodorisation process resulted in a mild tasting product free from fishy taste and free from chemical taste. If this product, however, is stored at low temperatures,

- 3 -

especially at the preferred temperature of about -18°C , it has turned out that this product is no longer readily flowable and becomes turbid which renders it esthetically less attractive and more difficult to handle because of its loss of homogeneity. This disadvantage, however, can be avoided by addition to the concentrate of an effective amount of a crystallization inhibitor, e.g., a lecithin or lecithin-like compound, before or after the deodorisation process.

Therefore, the present invention relates to a method of stabilising ester concentrates of polyunsaturated fatty acids (PUFAs) by adding to the concentrate (a) a mixture of rosemary or sage extract, ascorbyl palmitate and tocopherols before submitting it to a standard deodorisation process and (b) a crystallization inhibitor before or after the deodorisation process to stabilized PUFA ester concentrates thus obtained as well as to the use of the thus stabilized PUFA ester concentrates in food applications.

All percentages in the specification and claims unless otherwise specified are on a w/w basis.

The ester concentrates to be stabilised by the process of the present invention are commercially available products or can be prepared according to methods well-known in the art, e.g. from marine oils. For example, the manufacturer Ocean Nutrition, Canada, offers such concentrates which are produced from marine oils by interesterification with ethanol and subsequent distillation. They contain about 40-50% of ethyl EPA and about 20-30% of ethyl DHA. However, the present process can be applied to any concentrates of PUFA esters, preferably ethyl esters of n-3 and n-6 PUFAs, especially those which are of nutritive interest and importance but subject to degradation and development of undesirable off-flavors which would render them unsuitable for food application. Of particular interest with this respect are esters, especially the ethyl esters, of EPA and DHA.

The term "concentrate" relates to a broad concentration range and indicates that the content of a single ester or of mixtures of PUFA esters is higher than in a naturally occurring product. Preferred concentrates are those which consist of either synthetically produced PUFA esters of high purity or already refined products obtained from nature and free from the majority of naturally accompanying substances. In specifically interesting embodiments of the present invention the concentration of PUFA esters in concentrates to be stabilized is higher than 50%, e.g., in the range of 60-80%, and preferably at least 70%.

The term "crystallization inhibitor" in the present context is meant to encompass all compounds which are known to and used to inhibit the crystallization of edible oils or

their components at low temperatures, viz. temperatures below room temperature, especially when such oils are stored in refrigerators or deep-freezers, i.e. at temperatures at least as low as -18°C. The crystallization inhibitors when added to the concentrates will keep the oily concentrates in a readily flowable phase. Examples of preferred crystallization inhibitors useful in the context of the present invention are lecithins. The term "lecithin" is well-known in the art. However, it covers not only the compounds in the strictly scientific sense, viz. pure phosphatidyl cholines, but also products which are mixtures of different components which are defined according to the original source and the purification process by which they are obtained and which vary in their constituents both qualitatively and quantitatively (see, e.g., Kirk-Othmer, Encyclopedia of Chemical Technology, 4th edition, vol. 15, p. 192 - 194). Therefore, while pure phosphatidyl cholines can be used as well as all highly pure natural or synthetic mixtures of components covered by the term "lecithin" it is conceivable that from an economical point of view those products are preferred which are properly refined, i.e.,

to an extent that they have practically no odor, a bland taste and a light or no colour. Therefore, any food-grade or cosmetic-grade lecithin can be used in the present invention. It is, however, preferred to use a solid and/or liquid food-grade lecithin which is commercially available. Examples of such preferred lecithins are Epikuron ® 100G (Lucas Meyer, D-2000 Hamburg, Germany) and Topcithin ® (Lucas Meyer, D-2000 Hamburg, Germany).

The effective amount of lecithin to be added before or after the deodorisation process can easily be determined by the person skilled in the art and is normally in the range of 0.01% to 1.0%, preferably from 0.02% to 0.05%.

Any deodorisation vessel which is commercially available or any vessel which is large enough and fitted with the necessary components to carry through the process of the present invention can be used.

The other components which are added to the PUFA ester concentrate before deodorisation according to the present process are also well-known to a person skilled in the art and commercially available. The amounts of the components to be added are

- 0.05 - 4.0%, preferably about 0.1% to 0.2%, for rosemary or sage extract;
- 0.01 - 0.04%, preferably about 0.025%, for ascorbyl palmitate and
- 0.05 - 0.5%, preferably about 0.2%, for a tocopherol (α - β -, γ - or δ - tocopherol or mixtures thereof), preferably γ -tocopherol.

Any standard deodorisation process can be used which is known, e.g. for the deodorisation of marine oils, the preferred process being soft vacuum steam deodorisation. After deaeration of the mixture by applying a vacuum of about 5 – 10 mbar steam is injected and the process is conducted for 1 to 5 hours, preferably for 2 hours, at a temperature between about 120°C and 150°C depending on the vacuum and the volatility of the PUFA esters, normally between 0.1 and 10 mbar. A temperature of about 140°C at about 1-5 mbar is usually preferred, especially for the deodorisation of EPA and DHA ethyl ester concentrates.

Using the Rancimat (described, e.g., in European patent application publication No. 999 259) the stability of the product obtained in accordance with the present process can be determined and its advantageous properties compared with products obtained by prior art processes.

The PUFA ester concentrates stabilised according to the process of the present invention can be used for the preparation of food applications, including dietary supplements, and animal feed products. Examples of such food applications are given, e.g., in European patent application publication No. 999 259. By adding the stabilized PUFA ester concentrates of the present invention using methods known in the art to food, the food is enriched with these esters and thus improved.

- 8 -

induction time of 10.15 hours. It remained liquid at -18°C . The sample had a fish taste of 1 according to the FAST index.

Claims

1. A method of stabilising ester concentrates of polyunsaturated fatty acids (PUFAs) by adding to the concentrate (a) a mixture of rosemary or sage extract, ascorbyl palmitate and tocopherols before submitting it to a standard deodorisation process and (b) a crystallization inhibitor before or after the deodorisation process.
2. The method of claim 1 wherein further additives, able to prevent deterioration of PUFAs, are added to the concentrate before or after the deodorisation process.
3. The method of claim 1 wherein the ester concentrates are ethyl esters.
4. The method of claim 1 or claim 3, wherein a concentrate of ethyl esters of EPA and DHA is deodorized.
5. The method of anyone of claims 1 – 4, wherein the concentrate contains more than 50% of PUFA ethyl esters.
6. The method of anyone of claims 1 – 5, wherein 0.05 – 4.0%, preferably 0.1 – 0.2%, of rosemary or sage extract is added.
7. The method of anyone of claims 1 – 6, wherein 0.01 – 0.04%, preferably 0.025%, of ascorbyl palmitate is added.
8. The method of anyone of claims 1 – 7, wherein 0.05 – 0.5%, preferably 0.2%, of tocopherols is added.
9. The method of anyone of claims 1 – 8 wherein the crystallization inhibitor is a lecithin.
10. The method of claim 9 wherein 0.01% - 1.0%, preferably 0.02% - 0.05% of a lecithin is added.
11. The method of anyone of claims 2 – 10, wherein in addition 0.001 – 0.01%, preferably 0.005%, of citric acid is added.
12. The method of anyone of claims 1 – 11, wherein vacuum steam deodorisation is used.

- 10 -

13. The method of anyone of claims 1 – 12, wherein the vacuum steam deodorization is effected at a temperature between about 120°C and about 150°C at 0.1 – 10 mbar, most preferably at 140°C and 1 - 5 mbar.
- 5 14. Stabilized PUFA ester concentrates which are obtained by a method according to anyone of claims 1 – 13.
15. Use of a stabilized PUFA ester concentrate obtained according to a method claimed in anyone of claims 1 – 13 for the preparation of food applications.
- 10 16. A method of enriching food with PUFA esters characterized in that a stabilized PUFA ester concentrate according to claim 14 is added to the food.
